CliffBio
small molecule

NAROPIN

ROPIVACAINE HYDROCHLORIDE

Loss of exclusivityNovember 2026latest FDA-listed patent expiry
CompanyFresenius Kabi →View the full company profile on CliffBio

Drug detail

Brand nameNAROPIN
Active ingredientROPIVACAINE HYDROCHLORIDE
Strength400MG/200ML (2MG/ML)
Dosage formSOLUTION
RouteINJECTION
ModalitySmall molecule
FDA approvalSeptember 1996
Marketing statusRX

Listed patents

PatentExpiresType
7857802November 2026product

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NAROPIN patent cliff — loss of exclusivity November 2026 | CliffBio